2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

被引：255

作者：

Das, Sandeep R. ^{[1
]}

Everett, Brendan M. ^{[2
]}

Birtcher, Kim K. ^{[3
]}

Brown, Jenifer M. ^{[4
]}

Cefalu, William T. ^{[5
]}

Januzzi, James L., Jr. ^{[6
]}

Kalyani, Rita Rastogi ^{[7
]}

Kosiborod, Mikhail ^{[8
,9
]}

Magwire, Melissa L. ^{[10
]}

Morris, Pamela B. ^{[11
,12
]}

Sperling, Laurence S. ^{[13
,14
]}

Ahmad, Tariq

Hucker, William

Kumbhani, Dharam J.

Marine, Joseph E.

Piana, Robert N.

Rao, Sunil V.

Scherrer-Crosbie, Marielle

Watson, Karol E.

Wiggins, Barbara S.

机构：

[1] UT Southwestern Med Ctr, Med, Dallas, TX 75390 USA

[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[3] Univ Houston, Coll Pharm, Houston, TX 77030 USA

[4] Brigham & Womens Hosp, Cardiol, 75 Francis St, Boston, MA 02115 USA

[5] Amer Diabet Assoc, Arlington, VA USA

[6] Harvard Med Sch, Massachusetts Gen Hosp, Med, Boston, MA USA

[7] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD USA

[8] St Lukes Mid Amer Heart Inst, Kansas City, MO USA

[9] Univ Missouri, Med, Kansas City, MO 64110 USA

[10] Shawnee Mission Hlth Endocrine Clin, Merriam, KS USA

[11] Med Univ S Carolina, Cardiovasc Hlth Program, Charleston, SC 29425 USA

[12] Womens Heart Care, New York, NY USA

[13] Emory Heart Dis Prevent Ctr, Med Cardiol, Atlanta, GA USA

[14] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Global Hlth, Atlanta, GA 30322 USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2018年 / 72卷 / 24期

关键词：

ASCVD; cardiovascular risk reduction; diabetes; Expert Consensus Decision Pathway; GLP-1RA; SGLT2; inhibitor; T2D; PEPTIDE-1 RECEPTOR AGONISTS; REDUCED EJECTION FRACTION; ASSOCIATION TASK-FORCE; HEART-FAILURE; AMERICAN-COLLEGE; SGLT2; INHIBITORS; NA+/H+ EXCHANGER; DOUBLE-BLIND; EMPAGLIFLOZIN; OUTCOMES;

D O I：

10.1016/j.jacc.2018.09.020

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：3200 / 3223

页数：24

共 73 条

[11]

ClinicalTrials. gov, MK8835004 VERTIS CV

[12]

ClinicalTrials.gov, Effect of sotagliflozin on cardiovascular and renal events in participants with type 2 diabetes and moderate renal impairment who are at cardiovascular risk (SCORED)

[13]

ClinicalTrials. gov, EFF ALB ADD STAND BL

[14] Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone [J].

Davidson, Jaime A. .

DIABETES THERAPY, 2013, 4 (02) :221-238

[15] Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes [J].

Duckworth, William ;

Abraira, Carlos ;

Moritz, Thomas ;

Reda, Domenic ;

Emanuele, Nicholas ;

Reaven, Peter D. ;

Zieve, Franklin J. ;

Marks, Jennifer ;

Davis, Stephen N. ;

Hayward, Rodney ;

Warren, Stuart R. ;

Goldman, Steven ;

McCarren, Madeline ;

Vitek, Mary Ellen ;

Henderson, William G. ;

Huang, Grant D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) :129-U62

[16] Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program [J].

Erondu, Ngozi ;

Desai, Mehul ;

Ways, Kirk ;

Meininger, Gary .

DIABETES CARE, 2015, 38 (09) :1680-1686

[17] SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System [J].

Fadini, Gian Paolo ;

Avogaro, Angelo .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (09) :680-+

[18]

Fihn SD, 2012, J AM COLL CARDIOL, V60, pE44, DOI 10.1016/j.jacc.2012.07.013

[19] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Butler, Javed ;

van de Borne, Philippe ;

Zinman, Bernard ;

Lachin, John M. ;

Wanner, Christoph ;

Woerle, Hans J. ;

Hantel, Stefan ;

George, Jyothis T. ;

Johansen, Odd Erik ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. .

EUROPEAN HEART JOURNAL, 2018, 39 (05) :363-370

[20] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease [J].

Fitchett, David ;

Inzucchi, Silvio E. ;

Lachin, John M. ;

Wanner, Christoph ;

van de Borne, Philippe ;

Mattheus, Michaela ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

George, Jyothis T. ;

Zinman, Bernard .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) :364-367

← 1 2 3 4 5 6 7 8 →